Construction and validation of a ubiquitination-related prognostic risk score signature in breast cancer

被引:0
|
作者
Feng, Kexin [1 ]
He, Xin [1 ]
Qin, Ling [1 ]
Ma, Zihuan [2 ]
Liu, Siyao [2 ]
Jia, Ziqi [1 ]
Ren, Fei [1 ]
Cao, Heng [1 ]
Wu, Jiang [1 ]
Ma, Dongxu [1 ]
Wang, Xiang [1 ]
Xing, Zeyu [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Breast Surg Oncol, Beijing 100021, Peoples R China
[2] Beijing ChosenMed Clin Lab Co Ltd, Econ & Technol Dev Area, Jinghai Ind Pk, Beijing 100176, Peoples R China
关键词
Breast cancer; Biomarker; Risk score; Prognosis; Ubiquitination; SURVIVAL; LIGASES;
D O I
10.1016/j.heliyon.2024.e35553
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Breast cancer (BC) is a highly common form of cancer that occurs in many parts of the world. However, early -stage BC is curable. Many patients with BC have poor prognostic outcomes owing to ineffective diagnostic and therapeutic tools. The ubiquitination system and associated proteins were found influencing the outcome of individuals with cancer. Therefore, developing a biomarker associated with ubiquitination genes to forecast BC patient outcomes is a feasible strategy. Objective: The primary goal of this work was to develop a novel risk score signature capable of accurately estimate the future outcome of patients with BC by targeting ubiquitinated genes. Methods: Univariate Cox regression analysis was conducted utilizing the E1, E2, and E3 ubiquitination-related genes in the GSE20685 dataset. Genes with p < 0.01 were screened again using the Non-negative Matrix Factorization (NMF) algorithm, and the resulting hub genes were composed of a risk score signature. Patients were categorized into two risk groups, and the predictive effect was tested using Kaplan-Meier (KM) and Receiver Operating Characteristic (ROC) curves. This risk score signature was later validated using multiple external datasets, namely TCGA-BRAC, GSE1456, GSE16446, GSE20711, GSE58812 and GSE96058. Immunomicroenvironmental, single-cell, and microbial analyses were also performed. Results: The selected gene signature comprising six ubiquitination-related genes (ATG5, FBXL20, DTX4, BIRC3, TRIM45, and WDR78) showed good prognostic power in patients with BC. It was validated using multiple externally validated datasets, with KM curves showing significant differences in survival (p < 0.05). The KM curves also demonstrated superior predictive ability compared to traditional clinical indicators. Single-cell analysis revealed that Vd2 gd T cells were less abundantin the low-risk group, whereas patients in the high-risk group lacked myeloid dendritic cells. Tumor microbiological analysis revealed a notable variation in microorganism diversity between the high- and low-risk groups. Conclusion: This study established an risk score signature consisting of six ubiquitination genes, that can accurately forecast the outcome of patients with BC using multiple datasets. It can provide personalized and targeted assistance to provide the evaluation and therapy of individuals having BC.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Prognostic implication and immunotherapy response prediction of a ubiquitination-related gene signature in breast cancer
    Hong, Kai
    Chen, Qiaoqiao
    Zhang, Yingjue
    Cheng, Xu
    Cen, Kenan
    Dai, Ying
    Mai, Yifeng
    Guo, Yangyang
    FRONTIERS IN GENETICS, 2023, 13
  • [2] Gene signature and prognostic value of ubiquitination-related genes in endometrial cancer
    Ziwei Wang
    Shuangshuang Cheng
    Yan Liu
    Rong Zhao
    Jun Zhang
    Xing Zhou
    Wan Shu
    Dilu Feng
    Hongbo Wang
    World Journal of Surgical Oncology, 21
  • [3] Gene signature and prognostic value of ubiquitination-related genes in endometrial cancer
    Wang, Ziwei
    Cheng, Shuangshuang
    Liu, Yan
    Zhao, Rong
    Zhang, Jun
    Zhou, Xing
    Shu, Wan
    Feng, Dilu
    Wang, Hongbo
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [4] Development and validation of a novel ubiquitination-related gene prognostic signature based on tumor microenvironment for colon cancer
    Huang, Baoyi
    Deng, Weiping
    Chen, Pengfei
    Mao, Qiuxian
    Chen, Hao
    Zhuo, Zewei
    Huang, Zena
    Chen, Kequan
    Huang, Jiayu
    Luo, Yujun
    TRANSLATIONAL CANCER RESEARCH, 2022, : 3724 - 3740
  • [5] Identification of ubiquitination-related gene classification and a novel ubiquitination-related gene signature for patients with triple-negative breast cancer
    Zhao, Kankan
    Zheng, Yuan
    Lu, Wenliang
    Chen, Bo
    FRONTIERS IN GENETICS, 2023, 13
  • [6] Construction and validation of an immunity-related prognostic signature for breast cancer
    Zhu, Tao
    Zheng, Juyan
    Hu, Shuo
    Zhang, Wei
    Zhou, Honghao
    Li, Xi
    Liu, Zhao-Qian
    AGING-US, 2020, 12 (21): : 21597 - 21612
  • [7] Identification and validation of ubiquitination-related signature and subgroups in immune microenvironment of tuberculosis
    Zhou, Peipei
    Shen, Jie
    Ge, Xiao
    Cheng, Haien
    Sun, Yanli
    Li, Meng
    Li, Heng
    Yi, Zhengjun
    Li, Zhenpeng
    AGING-US, 2023, 15 (21): : 12570 - 12587
  • [8] Prognostic implication and immunotherapy response prediction of a ubiquitination-related gene signature in breast cancer (vol 13, 1038207, 2023)
    Guo, Yangyang
    Chen, Qiaoqiao
    Zhang, Yingjue
    Cheng, Xu
    Cen, Kenan
    Dai, Ying
    Mai, Yifeng
    Hong, Kai
    FRONTIERS IN GENETICS, 2023, 14
  • [9] Construction and Validation of Novel Ferroptosis-related Risk Score Signature and Prognostic Prediction Nomogram for Patients with Colorectal Cancer
    Liu, Ruibin
    Wang, Yue
    Bu, Jiawen
    Li, Qingqing
    Chen, Fang
    Zhu, Mengying
    Chi, Huanyu
    Yu, Guilin
    Zhu, Tong
    Zhu, Xudong
    Zhao, Guohua
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2024, 21 (06): : 1103 - 1116
  • [10] Prognostic Signature, Immune Features, and Therapeutic Responses of a Novel Ubiquitination-Related Gene Signature in Lung Adenocarcinoma
    Xu, Muge
    Gong, Jiening
    JOURNAL OF ONCOLOGY, 2022, 2022